BACKGROUND: @entity1749 , a @entity36763 dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity. METHODS: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 @entity1 with relapsed @entity1582 that was refractory to the therapy they had received most recently. @entity1 received 1.3 mg of @entity1749 per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles (24 weeks). In @entity1 with a suboptimal response, oral @entity619 (20 mg daily, on the day of and the day after @entity1749 administration) was added to the regimen. The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. RESULTS: Of 193 @entity1 who could be evaluated, 92 percent had been treated with three or more of the major classes of agents for @entity1582 , and in 91 percent, the @entity1582 was refractory to the therapy received most recently. The rate of response to @entity1749 was 35 percent, and those with a response included 7 @entity1 in whom @entity1582 protein became undetectable and 12 in whom @entity1582 protein was detectable only by immunofixation. The median overall survival was 16 months, with a median duration of response of 12 months. Grade 3 adverse events included @entity882 (in 28 percent of @entity1 ), @entity1295 (in 12 percent), @entity1897 (in 12 percent), and @entity1398 (in 11 percent). Grade 4 events occurred in 14 percent of @entity1 . CONCLUSIONS: @entity1749 , a member of a new class of anticancer drugs, is active in @entity1 with relapsed multiple @entity1582 that is refractory to conventional chemotherapy.

A phase 2 study of XXXX in relapsed, refractory @entity1582 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity36763 :: ('CHEBI:38267', 'Chemical') :: ['boronic acid'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib', 'Bortezomib']
@entity1749 :: (MESH:C400082,Chemical) :: ['bortezomib']
